IcoSema vs Insulin Efsitora Alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
Reported efficacy
Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)
Result source: NCT06269107
Insulin Efsitora Alfa · Onswik
Marketed by Eli Lilly
NCT05275400 · Phase 3 · completed
The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)
Result source: NCT05662332
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | IcoSema | Insulin Efsitora Alfa |
|---|---|---|
| HbA1c, change | -1.6% vs -0.9%vs Insulin IcodecNCT053528152 other results
| -1.3% vs -1.2%vs Insulin DegludecNCT0536205811 other results
|
| Body weight, change (kg) | -3.7 vs 2.0vs Insulin IcodecNCT053528151 other result
| 3.6 vs 3.5vs Insulin DegludecNCT053620586 other results
|
| HbA1c below 7% | —Not posted · NCT05013229 | —Not reported |
| Fasting plasma glucose, change | -1.9 vs -1.6vs Insulin IcodecNCT053528151 other result
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT05013229 | —Not reported |
HbA1c, change
- IcoSema
- -1.6% vs -0.9%vs Insulin IcodecNCT05352815
2 other results
- -1.4% vs -0.9% NCT05259033
- -1.5% vs -1.4% NCT05013229
- Insulin Efsitora Alfa
- -1.3% vs -1.2%vs Insulin DegludecNCT05362058
11 other results
- -1.2% vs -1.2% NCT05662332
- -0.8% vs -0.7% NCT05275400
- -1.0% vs -1% NCT05462756
- -1.3% vs -1.2% NCT05362058
- -1.2% vs -1.2% NCT05662332
- -0.8% vs -0.7% NCT05275400
- -1.4% vs -1.3% NCT05362058
- -1.0% vs -1% NCT05462756
- -0.6% vs -0.7% NCT03736785
- -0.6% vs -0.7% NCT03736785
- -1.2% vs -1.3% NCT04450394
Body weight, change (kg)
- IcoSema
- -3.7 vs 2.0vs Insulin IcodecNCT05352815
1 other result
- 0.9 vs -3.8 NCT05259033
- Insulin Efsitora Alfa
- 3.6 vs 3.5vs Insulin DegludecNCT05362058
6 other results
- 3.9 vs 3.3 NCT05662332
- 2.3 vs 2.2 NCT05275400
- 3.2 vs 2.7 NCT05362058
- 2.7 vs 2.5 NCT05462756
- 1 vs 2 NCT03736785
- 1 vs 2 NCT03736785
HbA1c below 7%
- IcoSema
- —Not posted · NCT05013229
- Insulin Efsitora Alfa
- —Not reported
Fasting plasma glucose, change
- IcoSema
- -1.9 vs -1.6vs Insulin IcodecNCT05352815
1 other result
- -2.7 vs -1.4 NCT05259033
- Insulin Efsitora Alfa
- —Not reported
3-point MACE (% with event)
- IcoSema
- —Not posted · NCT05013229
- Insulin Efsitora Alfa
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. IcoSema: 6 of 7 rows · Insulin Efsitora Alfa: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | IcoSema | Insulin Efsitora Alfa Rows use multiple source trials |
|---|---|---|
| Time Above Range absolute value · % of time | 23.2 vs 36.7 Insulin Icodec % of time @ 52wka NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 29.66 vs 33.05 Insulin Degludec % of time @ 52wka NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Time Below Range absolute value · % of time | 0.27 vs 0.33 Insulin Icodec % of time @ 52wka,b NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 0.36 vs 0.22 Insulin Degludec % of time @ 26wk500 U/mLa,b NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1 other source trial6.84 vs 5.25 Insulin Glargine % of time @ 26wk NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| Time in Range absolute value · percentage points | 75.9% (n=481) vs 61.9% (n=488) Insulin Icodec @ 52wka NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 64.27% (n=387) vs 61.18% (n=381) Insulin Degludec @ 52wka NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Dropout rate | 5.4% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result3.8% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 9.5%500 U/mLc NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results5.4% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 8.8%Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 4.7% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 0%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 12.6%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 12.9%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result— NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 1.1%500 U/mLc NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results0.6% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.8% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 0%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 0.7%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 0.8%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 9.2% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 15.7%500 U/mLc NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results8.8% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.5%Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.8% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.7%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 7.1%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 5.2%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 6.1%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | nausea 23.8% diarrhoea 15.8% vomiting 10.6% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more resultcovid-19 15% nausea 11.7% diarrhoea 11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 500 U/mLc covid-19 10.7% nasopharyngitis 9.2% dose calculation error 6.4% NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 7 more resultsnasopharyngitis 9.2% covid-19 7.9% upper respiratory tract infection 7.9% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 influenza 7.3% covid-19 5.3% hypertension 5.3% NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 4.7% arthralgia 2.3% diarrhoea 2.3% NCT04450394 · Phase 2 · registry result, not featured evidence abdominal discomfort 7.1% anaemia 7.1% chest pain 7.1% NCT04450394 · Phase 2 · registry result, not featured evidence diarrhoea 6.7% upper respiratory tract infection 5.9% cough 0.7% NCT03736785 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 10.6% diarrhoea 6.1% dizziness 5.3% NCT03736785 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation context differs: baseline_threshold differs (bmi<=45 versus bmi<=40, hba1c<=10, hba1c>=7).
- bAssessment timepoints differ: 26 weeks versus 52 weeks.
- cPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
IcoSema
show 1 more result
Insulin Efsitora Alfa
show 4 more results
show 3 more results
show 2 more results
show 1 more result
show 1 more result
show 2 more results
show 2 more results
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IcoSema's landscape · Insulin Efsitora Alfa's landscape